Showing 715 results
-
Media Release /
-
Media Release /- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due…
-
Media Release /
-
Media Release /- New intraocular lens (IOL) combines two technologies that correct for presbyopia and corneal astigmatism simultaneously- This IOL is a new option for patients who desire good near, intermediate and…
-
Media Release /
-
Media Release /Sunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® NeohalerNovartis will continue to manufacture these important medicines for SunovionIn line with…
-
Media Release /
-
Media Release /- 82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA)- ELIANA, the first global CAR T cell…
-
Media Release /
-
Media Release /Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril (1)These…
